JMI LABS IS NOW PART OF LEARN MORE

Intrinsic Resistance Mechanisms Detected Among Ceftazidime-Avibactam-Susceptible and -Resistant Pseudomonas aeruginosa Isolates Collected from United States Hospitals (2015)

Intrinsic Resistance Mechanisms Detected Among Ceftazidime-Avibactam-Susceptible and -Resistant Pseudomonas aeruginosa Isolates Collected from United States Hospitals (2015). Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA.
#Sunday-166

Antimicrobial Activity of Ceftobiprole When Tested against Isolates from Diabetic Foot Infections (2013-2016)

Antimicrobial Activity of Ceftobiprole When Tested against Isolates from Diabetic Foot Infections (2013-2016). Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-6

Aminoglycoside-Resistance Genes Among 2014-2015 US Carbapenem-Resistant Enterobacteriaceae Isolates and Activity of Plazomicin against Characterized Isolates

Aminoglycoside-Resistance Genes Among 2014-2015 US Carbapenem-Resistant Enterobacteriaceae Isolates and Activity of Plazomicin against Characterized Isolates. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-9

Antimicrobial Susceptibility Trends among Staphylococcus aureus from US Hospitals: Results from 7 years of the Ceftaroline (AWARE) Surveillance Program (2009-2015)

Antimicrobial Susceptibility Trends among Staphylococcus aureus from US Hospitals: Results from 7 years of the Ceftaroline (AWARE) Surveillance Program (2009-2015). Lead author: H Sader presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-142

Activity of Solithromycin and Comparators against Respiratory Tract Pathogens Collected in the 2016 Global SENTRY Surveillance Program

Activity of Solithromycin and Comparators against Respiratory Tract Pathogens Collected in the 2016 Global SENTRY Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-7

Antimicrobial Activity of Ceftobiprole When Tested against Contemporary Isolates from US Medical Centers (2016)

Antimicrobial Activity of Ceftobiprole When Tested against Contemporary Isolates from US Medical Centers (2016). Lead author: R Flamm, presented at ASM Microbe 2017, New Orleans, Louisiana, USA
# Sunday-12

Updated Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bloodstream Infections in United States and European Hospitals (2014-2016)

Updated Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bloodstream Infections in United States and European Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-33

Potentiation of Clarithromycin When Combined with a New Cationic Peptide against Gram-negative Clinical Isolates and Molecular Analysis of Macrolide Resistance Mechanisms by Next-Generation Sequencing

Potentiation of Clarithromycin When Combined with a New Cationic Peptide against Gram-negative Clinical Isolates and Molecular Analysis of Macrolide Resistance Mechanisms by Next-Generation Sequencing. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-162

Synergistic Effect of Novel Gyrase Inhibitor Agents (SPR750 and SPR751) in Combination with a Polymyxin Derivative (SPR741) against Recent Acinetobacter baumannii and Enterobacteriaceae

Synergistic Effect of Novel Gyrase Inhibitor Agents (SPR750 and SPR751) in Combination with a Polymyxin Derivative (SPR741) against Recent Acinetobacter baumannii and Enterobacteriaceae. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-13

In vitro Antibacterial Activity of Omadacycline and Comparators against Key Respiratory, Skin and Skin Structure, and Urinary Tract Pathogens Collected from the United States and Europe during the 2016 SENTRY Antimicrobial Surveillance Program

In vitro Antibacterial Activity of Omadacycline and Comparators against Key Respiratory, Skin and Skin Structure, and Urinary Tract Pathogens Collected from the United States and Europe during the 2016 SENTRY Antimicrobial Surveillance Program. Lead author: M Huband presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-45

Multilaboratory Broth Microdilution MIC Reproducibility Study for GSK3342830, a Novel Catechol-Cephem

Multilaboratory Broth Microdilution MIC Reproducibility Study for GSK3342830, a Novel Catechol-Cephem. Lead author: P Rhomberg, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-287

Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against Pseudomonas aeruginosa, Klebsiella spp., and Escherichia coli Isolates Collected in Asia-Pacific, North and Latin America, and Europe from 2011-2016

Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against Pseudomonas aeruginosa, Klebsiella spp., and Escherichia coli Isolates Collected in Asia-Pacific, North and Latin America, and Europe from 2011-2016. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-29

Antimicrobial Activity of Meropenem-WCK 4234 (WCK 5999) against Clinical Isolates of Acinetobacter spp. Collected Worldwide and Stratified by Infection Type

Antimicrobial Activity of Meropenem-WCK 4234 (WCK 5999) against Clinical Isolates of Acinetobacter spp. Collected Worldwide and Stratified by Infection Type. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Saturday-97

Fosfomycin In Vitro Activity against Bacteria with Various Mechanisms of Resistance to Other Antibacterials from US Hospitals

Fosfomycin In Vitro Activity against Bacteria with Various Mechanisms of Resistance to Other Antibacterials from US Hospitals. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-61

Evaluation of Fosfomycin Activity When Combined with Selected Antimicrobial Agents and Tested against Bacterial Isolates Using Checkerboard Methods

Evaluation of Fosfomycin Activity When Combined with Selected Antimicrobial Agents and Tested against Bacterial Isolates Using Checkerboard Methods. Lead author: P Rhomberg, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-406

Activity of Fusidic Acid against Recent Clinical Isolates of Staphylococci Collected from United States Hospitals in 2016 as Part of the SENTRY Antimicrobial Surveillance Program

Activity of Fusidic Acid against Recent Clinical Isolates of Staphylococci Collected from United States Hospitals in 2016 as Part of the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-56

In Vitro Activity of LYS228 against Enterobacteriaceae, Including Molecularly Characterized Multidrug-Resistant Isolates

In Vitro Activity of LYS228 against Enterobacteriaceae, Including Molecularly Characterized Multidrug-Resistant Isolates. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-293

Fosfomycin Activity When Tested against Gram-Positive and Gram-Negative US Isolates Collected by the SENTRY Antimicrobial Surveillance Program

Fosfomycin Activity When Tested against Gram-Positive and Gram-Negative US Isolates Collected by the SENTRY Antimicrobial Surveillance Program. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-57

Correlation of Reference Agar Dilution MIC Values and Kirby-Bauer Disk Diffusion Testing for Fosfomycin against Gram-Positive and Gram-Negative Bacteria

Correlation of Reference Agar Dilution MIC Values and Kirby-Bauer Disk Diffusion Testing for Fosfomycin against Gram-Positive and Gram-Negative Bacteria. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-411

Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents

Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-414

Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates, Including Carbapenem-Resistant and Carbapenemase-Producing Isolates, Collected in United States (US) Hospitals During 2016

Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates, Including Carbapenem-Resistant and Carbapenemase-Producing Isolates, Collected in United States (US) Hospitals During 2016. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-58

Tedizolid Activity against Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis in United States and European Hospitals (2014-2016)

Tedizolid Activity against Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis in United States and European Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-341

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Pseudomonas aeruginosa Isolates with Various Resistant Phenotypes from US Hospitals

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Pseudomonas aeruginosa Isolates with Various Resistant Phenotypes from US Hospitals. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-50

Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2015)

Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2015). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-129

Meropenem-Vaborbactam (CarbavanceTM) MIC and Zone Diameter Quality Control Ranges Using a CLSI M23-A4 Multi-Laboratory Study Design

Meropenem-Vaborbactam (CarbavanceTM) MIC and Zone Diameter Quality Control Ranges Using a CLSI M23-A4 Multi-Laboratory Study Design. Lead author: M Huband, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-417

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) When Tested against Bacterial Isolates from Patients Hospitalized with Pneumonia

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) When Tested against Bacterial Isolates from Patients Hospitalized with Pneumonia. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-52

Susceptibility of Ceftolozane-Tazobactam against Isolates Collected from Intensive Care Unit Patients in US Hospitals from 2014-2016

Susceptibility of Ceftolozane-Tazobactam against Isolates Collected from Intensive Care Unit Patients in US Hospitals from 2014-2016. Lead author: M Pfaller, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-76

Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents

Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-414

Impact of Changes in Growth Medium, Inoculum Density, and Incubation Conditions on the In Vitro Antimicrobial Activity of Plazomicin

Impact of Changes in Growth Medium, Inoculum Density, and Incubation Conditions on the In Vitro Antimicrobial Activity of Plazomicin. Lead author: L Duncan presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-410

In Vitro Activity and Potency of the Novel Oxazolidinone MRX-I Tested against Contemporary Clinical Isolates of Gram-Positive Bacteria

In Vitro Activity and Potency of the Novel Oxazolidinone MRX-I Tested against Contemporary Clinical Isolates of Gram-Positive Bacteria. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-343

Oritavancin In Vitro Activity Against a Collection of Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis, in United States and European Hospitals (2012-2016)

Oritavancin In Vitro Activity Against a Collection of Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis, in United States and European Hospitals (2012-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-342

Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Isolates Harboring β-Lactamase Genes Detected Using Whole Genome Sequencing Analysis

Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Isolates Harboring β-Lactamase Genes Detected Using Whole Genome Sequencing Analysis. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-57

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Infections in United States Hospitals (2014-2016)

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Infections in United States Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-340

WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against gram-negative organisms producing clinically relevant beta-lactamases.

WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against gram-negative organisms producing clinically relevant beta-lactamases. by Sader HS, Rhomberg PR, Flamm RK, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2017; 72 (6): 1696-1703

Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012-2015) of the International Network for Optimal Resistance Monitoring program in the United States.

Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012-2015) of the International Network for Optimal Resistance Monitoring program in the United States. by Sader HS, Huband MD, Castanheira M and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (3): e02252

Antimicrobial activity of high-proportion cefepime-tazobactam (WCK 4282) against a large number of gram-negative isolates collected worldwide in (2014).

Antimicrobial activity of high-proportion cefepime-tazobactam (WCK 4282) against a large number of gram-negative isolates collected worldwide in (2014). by Sader HS, Castanheira M, Mendes RE, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2017; 61 (4): e02409

Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).

Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). by Sader HS, Castanheira M, Jones RN and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2017; 87 (3): 261-265

WCK 5222 (cefepime-zidebactam) antimicrobial activity tested against clinical isolates of gram-negative bacteria collected worldwide (2015).

WCK 5222 (cefepime-zidebactam) antimicrobial activity tested against clinical isolates of gram-negative bacteria collected worldwide (2015). by Sader HS, Castanheira M, Huband M, Jones RN and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (5): 00072

Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2011-2015).

Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2011-2015). by Sader HS, Castanheira M and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (4): e02083

Activities of omadacycline and comparator agents when tested against Staphylococcus aureus from a surveillance program conducted in North America and Europe.

Activities of omadacycline and comparator agents when tested against Staphylococcus aureus from a surveillance program conducted in North America and Europe. by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (3): e02411

Activity of a long-acting Echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY (2014) Antifungal Surveillance Program.

Activity of a long-acting Echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY (2014) Antifungal Surveillance Program. by Pfaller MA, Messer SA, Rhomberg PR and Castanheira M published in Antimicrob. Agents Chemother. 2017; 61 (3): e02045

Ceftaroline activity against multidrug-resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and molecular characterization of a single ceftaroline nonsusceptible isolate.

Ceftaroline activity against multidrug-resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and molecular characterization of a single ceftaroline nonsusceptible isolate. by Pfaller MA, Mendes RE, Flamm RK, Jones RN and Sader HS published in Microb. Drug Resist. 2017; 23 (5): 571-579

Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012-2014.

Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012-2014. by Pfaller MA, Mendes RE, Castanheira M, Flamm RK, Jones RN and Sader HS published in Pediatr. Infect. Dis. J. 2017; 36 (5): 486-491

Surveillance of omadacycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Western Pacific) collection (2010-2011).

Surveillance of omadacycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Western Pacific) collection (2010-2011). by Pfaller MA, Huband MD, Rhomberg PR and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (5): e00018-00017

Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014).

Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014). by Pfaller MA, Flamm RK, Duncan LR, Mendes RE, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2017; 88 (2): 177-183

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: Report from an antimicrobial surveillance programme (2012-15).

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: Report from an antimicrobial surveillance programme (2012-15). by Pfaller MA, Bassetti M, Duncan LR and Castanheira M published in J. Antimicrob. Chemother. 2017; 72 (5): 1386-1395

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014).

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014). by Mendes RE, Sader HS, Smart JI, Castanheira M and Flamm RK published in Eur. J. Clin. Microbiol. Infect. Dis. 2017; 36 (6): 1013-1017

Molecular beta-lactamase characterization of aerobic Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections, with efficacies analyzed against susceptible and resistant subsets.

Molecular beta-lactamase characterization of aerobic Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections, with efficacies analyzed against susceptible and resistant subsets. by Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (6): e02447-16

Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents.

Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. by Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Glob. Antimicrob. Resist. 2017; 8: 28-32

Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/beta-lactam combinations.

Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/beta-lactam combinations. by McLeod SM, Patey SA, Huband MD and Nichols WW published in Int. J. Antimicrob. Agents. 2017; 49 (4): 437-442